{"id":"W2989830802","doi":"10.1016/j.euo.2019.11.001","title":"Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; CancerCare Manitoba; Health Sciences Centre; University of Manitoba; Princess Margaret Cancer Centre; University of Calgary","funders":"Instituto de Salud Carlos III; Genentech; Eisai; American Psychosocial Oncology Society; Exelixis; North Carolina GlaxoSmithKline Foundation; EMD Serono; Novartis; Merck; F. Hoffmann-La Roche; Roche; Astellas Pharma US; Health Research Fund of Central Denmark Region; Dana-Farber Cancer Institute; Pfizer; Ipsen Biopharmaceuticals; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Renal cell carcinoma; Oncology; Internal medicine; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004170112,0.0005655463,0.001482247,0.0003725008,0.00005108959,0.000006281447,0.0002246553,0.0001787242,0.0008180332],"category_scores_gemma":[0.00002658293,0.0003434529,0.0002163625,0.0003062054,0.0005252566,0.00007769604,0.0001140849,0.000472807,0.0003032779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003431885,"about_ca_system_score_gemma":0.0003817969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007021336,"about_ca_topic_score_gemma":0.00002731685,"domain_scores_codex":[0.9961026,0.001270947,0.0008434643,0.000761397,0.0003456868,0.000675907],"domain_scores_gemma":[0.9976688,0.0002905919,0.0006441572,0.0008064384,0.0003525552,0.0002374786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02097291,0.002595141,0.9602922,0.0000469858,0.0007667315,0.002278323,0.0009008361,0.00003079675,0.01001609,0.000005058912,0.0001606487,0.001934291],"study_design_scores_gemma":[0.02529319,0.05546147,0.8986765,0.00001032401,0.000607483,0.0001776774,0.0001063968,0.000007658946,0.01221353,0.000002965086,0.007154095,0.000288759],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791539,0.0006233805,0.0000142578,0.0004547319,0.0001836125,0.001648675,0.00002814847,0.00007353591,0.0178197],"genre_scores_gemma":[0.9960174,0.00002250859,0.00132798,0.001150341,0.0000505078,0.00007695792,0.0002043716,0.0001405057,0.001009446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06161574,"threshold_uncertainty_score":0.9999018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0106048798008899,"score_gpt":0.2301214897779839,"score_spread":0.219516609977094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}